Drug Profile
Research programme: small molecule drug conjugate cancer therapeutics - Molecular Targeting Technologies/National Health Research Institutes
Alternative Names: DPA-drug conjugates; Small molecule drug conjugate; SMDC; SMDC-T1; Synthetic zinc-dipicolylamine; T1; Zn-DPA drug conjugates; Zn-DPA-SN 38 conjugateLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Molecular Targeting Technologies; National Health Research Institutes
- Class Drug conjugates; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in Taiwan
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 07 Aug 2014 Research programme: small molecule drug conjugate cancer therapeutics - Molecular Targeting Technologies/National Health Research Institutes is available for licensing in World as of 07 Aug 2014. http://www.mtarget.com